genetics eco

Nexalife

Pharmaceuticals

newspaper Newsroom

Research & News Archive

Stay updated with the latest breakthroughs, corporate announcements, and scientific publications from Nexalife.

Press Release

calendar_month Oct 24, 2023 • Clinical Trials

Nexalife announces positive Phase 3 top-line results for NX-202 in Rare Disease

Significant improvements observed in primary endpoints, paving the way for regulatory submission later this year. The study demonstrated robust efficacy and a favorable safety profile across all patient cohorts.

Read Full Release arrow_forward

Partnership

calendar_month Sep 15, 2023 • Corporate

Strategic Partnership Announced with Global Health Institute

A new collaboration aimed at accelerating the discovery of novel targets in neurodegenerative diseases utilizing our proprietary screening platform and GHI's extensive biobank resources.

Read Announcement arrow_forward

Publication

calendar_month Aug 02, 2023 • Oncology

Novel Mechanism for Tumor Suppression Published in Nature Medicine

Our research team has identified a key pathway that regulates tumor growth in solid cancers. This discovery opens new avenues for therapeutic intervention using our small molecule library.

View Publication arrow_forward

Financials

calendar_month Jul 28, 2023 • Investors

Nexalife Reports Second Quarter 2023 Financial Results

Strong balance sheet maintained while advancing three clinical programs. Conference call to be held today at 8:00 AM ET to discuss operational highlights and future outlook.

Read Report arrow_forward

Press Release

calendar_month Jun 10, 2023 • Leadership

Appointment of Dr. Elena Rostova as Chief Scientific Officer

Dr. Rostova brings over 20 years of experience in gene therapy development. She will lead the expansion of our R&D capabilities and oversee the upcoming Phase 1 trials.

Read Full Release arrow_forward